Congenital amegakaryocytic thrombocytopenia
| Congenital amegakaryocytic thrombocytopenia | |
|---|---|
| Synonyms | CAMT |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Thrombocytopenia, bleeding, bruising |
| Complications | Bone marrow failure, leukemia |
| Onset | Neonatal |
| Duration | Lifelong |
| Types | N/A |
| Causes | Genetic mutation in the MPL gene |
| Risks | Family history |
| Diagnosis | Blood test, bone marrow biopsy, genetic testing |
| Differential diagnosis | Thrombocytopenia absent radius syndrome, Fanconi anemia |
| Prevention | N/A |
| Treatment | Hematopoietic stem cell transplantation, platelet transfusion |
| Medication | Thrombopoietin receptor agonists |
| Prognosis | N/A |
| Frequency | Rare |
| Deaths | N/A |
Congenital amegakaryocytic thrombocytopenia (CAT) is a rare genetic disorder characterized by a significant reduction in the number of platelets due to a failure of the bone marrow to produce megakaryocytes, the precursor cells to platelets. This condition is present at birth and is classified as a type of bone marrow failure syndrome.
Pathophysiology[edit]
Congenital amegakaryocytic thrombocytopenia is primarily caused by mutations in the MPL gene, which encodes the thrombopoietin receptor. Thrombopoietin is a crucial growth factor for the development of megakaryocytes. Mutations in the MPL gene lead to a lack of response to thrombopoietin, resulting in the absence or severe reduction of megakaryocytes in the bone marrow and consequently, thrombocytopenia.
Clinical Presentation[edit]
Patients with CAT typically present with symptoms related to low platelet counts, such as:
- Petechiae
- Ecchymosis
- Epistaxis
- Gingival bleeding
- Increased risk of intracranial hemorrhage
The condition is usually diagnosed in infancy or early childhood when these symptoms become apparent.
Diagnosis[edit]
The diagnosis of congenital amegakaryocytic thrombocytopenia involves:
- Complete blood count (CBC) showing isolated thrombocytopenia
- Bone marrow biopsy revealing a lack of megakaryocytes
- Genetic testing to identify mutations in the MPL gene
Management[edit]
Management of CAT focuses on supportive care and may include:
- Platelet transfusions to manage bleeding episodes
- Hematopoietic stem cell transplantation (HSCT) as a potential curative treatment
Prognosis[edit]
The prognosis for individuals with congenital amegakaryocytic thrombocytopenia varies. Without treatment, patients are at risk for severe bleeding complications. Hematopoietic stem cell transplantation can offer a cure, but the success of the procedure depends on various factors, including the availability of a suitable donor and the patient's overall health.
